Sanjiv Sam Gambhir, MD, PhD

Publication Details

  • Preclinical efficacy of the c-met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by F-18-FDG small-animal PET JOURNAL OF NUCLEAR MEDICINE Tseng, J. R., Kang, K. W., Dandekar, M., Yaghoubi, S., Lee, J. H., Christensen, J. G., Muir, S., Vincent, P. W., Michaud, N. R., Gambhir, S. S. 2008; 49 (1): 129-134

    Abstract:

    The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using (18)F-FDG small-animal PET.CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using (18)F-FDG small-animal PET and compared with tumor volume growth curves.The maximum %ID/g (percentage injected dose per gram of tissue) of (18)F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of (18)F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment.CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of (18)F-FDG PET to assess early tumor response for CE-355621.

    View details for DOI 10.2967/jnumed.106.038836

    View details for Web of Science ID 000252391700026

    View details for PubMedID 18077531

Stanford Medicine Resources:

Footer Links: